HomeCompareCEMI vs EPRT

CEMI vs EPRT: Dividend Comparison 2026

CEMI yields 439.56% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEMI wins by $23009.94M in total portfolio value
10 years
CEMI
CEMI
● Live price
439.56%
Share price
$0.46
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23010.00M
Annual income
$15,896,080,726.35
Full CEMI calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CEMI vs EPRT

📍 CEMI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCEMIEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CEMI + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CEMI pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CEMI
Annual income on $10K today (after 15% tax)
$37,362.64/yr
After 10yr DRIP, annual income (after tax)
$13,511,668,617.40/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CEMI beats the other by $13,511,657,702.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CEMI + EPRT for your $10,000?

CEMI: 50%EPRT: 50%
100% EPRT50/50100% CEMI
Portfolio after 10yr
$11505.03M
Annual income
$7,948,046,783.54/yr
Blended yield
69.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CEMI
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-3.4
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CEMI buys
0
EPRT buys
0
No recent congressional trades found for CEMI or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCEMIEPRT
Forward yield439.56%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$23010.00M$63.4K
Annual income after 10y$15,896,080,726.35$12,840.73
Total dividends collected$22371.64M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: CEMI vs EPRT ($10,000, DRIP)

YearCEMI PortfolioCEMI Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$54,656$43,956.04$11,205$505.18+$43.5KCEMI
2$283,011$224,529.30$12,672$682.46+$270.3KCEMI
3$1,389,385$1,086,562.63$14,490$930.48+$1.37MCEMI
4$6,471,924$4,985,282.48$16,786$1,282.69+$6.46MCEMI
5$28,627,815$21,702,856.71$19,753$1,791.56+$28.61MCEMI
6$120,351,485$89,719,722.14$23,677$2,541.64+$120.33MCEMI
7$481,282,796$352,506,707.51$29,008$3,672.99+$481.25MCEMI
8$1,832,417,590$1,317,444,998.11$36,463$5,425.08+$1832.38MCEMI
9$6,648,527,352$4,687,840,530.71$47,238$8,221.57+$6648.48MCEMI
10$23,010,004,993$15,896,080,726.35$63,385$12,840.73+$23009.94MCEMI

CEMI vs EPRT: Complete Analysis 2026

CEMIStock

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Full CEMI Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CEMI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CEMI vs SCHDCEMI vs JEPICEMI vs OCEMI vs KOCEMI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.